Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

N6-methyladenosine modified TGFB2 triggers lipid metabolism reprogramming to confer pancreatic ductal adenocarcinoma gemcitabine resistance

24 Jun 2024

Abstract excerpt

Gemcitabine resistance is a major obstacle to the effectiveness of chemotherapy in pancreatic ductal adenocarcinoma (PDAC). Therefore, new strategies are needed to sensitize cancer cells to gemcitabine. Here, we constructed gemcitabine-resistant PDAC cells and analyzed them with RNA-sequence. Employing an integrated approach involving bioinformatic analyses from multiple databases, TGFB2 is identified as a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Lipids, and Metabolism
Share to Pancreatic and Hepatic Oncology Research
Share to RNA modifications and cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38914663
DOI: 10.1038/s41388-024-03092-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

N6-methyladenosine modified TGFB2 triggers lipid metabolism reprogramming to confer pancreatic ductal adenocarcinoma gemcitabine resistancePMID 38914663Read ↗

Transforming growth factor beta‐induced, an extracellular matrix interacting protein, enhances glycolysis and promotes pancreatic cancer cell migrationSemantic proximity Read ↗

KDM5B promotes SMAD4 loss-driven drug resistance through activating DLG1/YAP to induce lipid accumulation in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Novel strategy for oncogenic alteration-induced lipid metabolism reprogramming in pancreatic cancer.Semantic proximity Read ↗

Insights into gemcitabine resistance in pancreatic cancer: association with metabolic reprogramming and TP53 pathogenicity in patient derived xenograftsSemantic proximity Read ↗

Inhibition of adipose tissue-derived fatty acid binding protein suppresses pancreatic cancer progression and metastasisSemantic proximity Read ↗

SMAD4 and the TGFβ Pathway in Patients with Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

Transglutaminases are oncogenic biomarkers in human cancers and therapeutic targeting of TGM2 blocks chemoresistance and macrophage infiltration in pancreatic cancerSemantic proximity Read ↗

Convergence for Inactivation of TGFβ Signaling Is a Common Feature of Advanced Pancreatic Cancer.Semantic proximity Read ↗

SREBP1 is associated with lipid-metabolic reprogramming and apoptotic regulation in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

ID1 Mediates Escape from TGFβ Tumor Suppression in Pancreatic CancerSemantic proximity Read ↗

Targeting tumor-intrinsic TAK1 triggers anti-tumor immunity and sensitizes pancreatic cancer to checkpoint blockadeSemantic proximity Read ↗

Systematic Single-Cell Dissection of Cell Cycle and TGFβ-Induced State Transitions Underlying Gemcitabine Resistance in 3D Pancreatic Tumor Tissue ModelsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.